Derk W. Krieger, MD, PhD

Derk W. Krieger, MD
Section of Stroke and Neurological Intensive Care, The Cleveland Clinic Foundation

Address: Derk W. Krieger, MD, Section of Stroke and Neurological Intensive Care, The Cleveland Clinic Foundation, S91, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org

Derk W. Krieger, MD
Section of Stroke and Neurological Intensive Care, The Cleveland Clinic Foundation

Address: Derk W. Krieger, MD, Section of Stroke and Neurological Intensive Care, The Cleveland Clinic Foundation, S91, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org

Derk W. Krieger, MD
Section of Stroke and Neurological Intensive Care, The Cleveland Clinic Foundation

Address: Derk W. Krieger, MD, Section of Stroke and Neurological Intensive Care, The Cleveland Clinic Foundation, S91, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org

Rishi Gupta, MD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Derk W. Krieger, MD, PhD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Address: Derk W. Krieger, MD, PhD, Department of Neurology, Section of Stroke and Neurological Critical Care, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org

Dr. Krieger has indicated that he is on the speakers’ bureau of BMS and is a consultant for Boehringer Ingleheim.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Rishi Gupta, MD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Derk W. Krieger, MD, PhD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Address: Derk W. Krieger, MD, PhD, Department of Neurology, Section of Stroke and Neurological Critical Care, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org

Dr. Krieger has indicated that he is on the speakers’ bureau of BMS and is a consultant for Boehringer Ingleheim.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Rishi Gupta, MD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Derk W. Krieger, MD, PhD
Department of Neurology, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation

Address: Derk W. Krieger, MD, PhD, Department of Neurology, Section of Stroke and Neurological Critical Care, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail krieged@ccf.org

Dr. Krieger has indicated that he is on the speakers’ bureau of BMS and is a consultant for Boehringer Ingleheim.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Derk W. Krieger, MD, PhD
Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation, Cleveland, OH

Correspondence: Derk W. Krieger, MD, PhD, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation, 9500 Euclid Avenue, S91, Cleveland, OH 44195; email: krieged@ccf.org

Derk W. Krieger, MD, PhD
Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation, Cleveland, OH

Correspondence: Derk W. Krieger, MD, PhD, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation, 9500 Euclid Avenue, S91, Cleveland, OH 44195; email: krieged@ccf.org

Derk W. Krieger, MD, PhD
Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation, Cleveland, OH

Correspondence: Derk W. Krieger, MD, PhD, Section of Stroke and Neurological Critical Care, The Cleveland Clinic Foundation, 9500 Euclid Avenue, S91, Cleveland, OH 44195; email: krieged@ccf.org

Maxim D. Hammer, MD
Department of Neurology, The Cleveland Clinic

Derk W. Krieger, MD, PhD
Section of Stroke and Neurologic Intensive Care, Department of Neurology, The Cleveland Clinic; Co-principal investigator, Cooling for Acute Ischemic Brain Damage (COOL AID) study

Address: Derk W. Krieger, MD, PhD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail kreiged@ccf.org

Dr. Krieger has indicated that he has received grant or research support from Radiant Medical Inc, is a consultant for Medcool, Inc, and is on the speakers’ bureaus of Sanofi-Synthelabo and the Bristol-Myers Squibb Company.

This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.

Maxim D. Hammer, MD
Department of Neurology, The Cleveland Clinic

Derk W. Krieger, MD, PhD
Section of Stroke and Neurologic Intensive Care, Department of Neurology, The Cleveland Clinic; Co-principal investigator, Cooling for Acute Ischemic Brain Damage (COOL AID) study

Address: Derk W. Krieger, MD, PhD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail kreiged@ccf.org

Dr. Krieger has indicated that he has received grant or research support from Radiant Medical Inc, is a consultant for Medcool, Inc, and is on the speakers’ bureaus of Sanofi-Synthelabo and the Bristol-Myers Squibb Company.

This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.

Maxim D. Hammer, MD
Department of Neurology, The Cleveland Clinic

Derk W. Krieger, MD, PhD
Section of Stroke and Neurologic Intensive Care, Department of Neurology, The Cleveland Clinic; Co-principal investigator, Cooling for Acute Ischemic Brain Damage (COOL AID) study

Address: Derk W. Krieger, MD, PhD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail kreiged@ccf.org

Dr. Krieger has indicated that he has received grant or research support from Radiant Medical Inc, is a consultant for Medcool, Inc, and is on the speakers’ bureaus of Sanofi-Synthelabo and the Bristol-Myers Squibb Company.

This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.